Guru Sonpavde outlines the findings of their immunotherapy study supporting a potential role for longitudinal ctDNA profiling to identify suitable therapies for people with metastatic urothelial cancer (4:43).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany